First Light Asset Management LLC Has $2.22 Million Position in IRIDEX Co. (IRIX)

First Light Asset Management LLC increased its stake in shares of IRIDEX Co. (NASDAQ:IRIX) by 22.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 387,687 shares of the medical equipment provider’s stock after buying an additional 69,888 shares during the quarter. First Light Asset Management LLC owned 3.33% of IRIDEX worth $2,218,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Renaissance Technologies LLC lifted its position in shares of IRIDEX by 12.8% during the 4th quarter. Renaissance Technologies LLC now owns 272,900 shares of the medical equipment provider’s stock worth $2,079,000 after buying an additional 31,000 shares during the period. Lyon Street Capital LLC lifted its position in shares of IRIDEX by 9.3% during the 4th quarter. Lyon Street Capital LLC now owns 483,760 shares of the medical equipment provider’s stock worth $3,686,000 after buying an additional 41,113 shares during the period. Deutsche Bank AG lifted its position in shares of IRIDEX by 31.6% during the 4th quarter. Deutsche Bank AG now owns 35,430 shares of the medical equipment provider’s stock worth $269,000 after buying an additional 8,509 shares during the period. Isthmus Partners LLC lifted its position in shares of IRIDEX by 10.0% during the 1st quarter. Isthmus Partners LLC now owns 88,464 shares of the medical equipment provider’s stock worth $506,000 after buying an additional 8,056 shares during the period. Finally, Blair William & Co. IL bought a new position in shares of IRIDEX during the 1st quarter worth approximately $249,000. Institutional investors and hedge funds own 48.84% of the company’s stock.

Shares of IRIDEX opened at $7.03 on Thursday, according to MarketBeat. IRIDEX Co. has a 52-week low of $4.28 and a 52-week high of $10.98. The firm has a market capitalization of $81.46 million, a price-to-earnings ratio of -6.33 and a beta of 1.42.

IRIDEX (NASDAQ:IRIX) last issued its quarterly earnings data on Thursday, May 3rd. The medical equipment provider reported ($0.31) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.02. IRIDEX had a negative return on equity of 44.78% and a negative net margin of 35.95%. The firm had revenue of $9.51 million during the quarter, compared to the consensus estimate of $8.80 million. equities research analysts expect that IRIDEX Co. will post -1.16 earnings per share for the current year.

Separately, Zacks Investment Research downgraded IRIDEX from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.

Want to see what other hedge funds are holding IRIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IRIDEX Co. (NASDAQ:IRIX).

Institutional Ownership by Quarter for IRIDEX (NASDAQ:IRIX)

Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit